During the diagnosis, each patient with Crohn’s disease or ulcerative colitis experiences major crises. However, each of them will not have a unique course of their disease.

Within the framework of personalized medicine implemented with the follow-up of biotherapies, we have the opportunity to deploy a therapeutic arsenal totally adapted to each patient from the diagnosis of his disease.

The PredicSURE IBD ™ test developed by the company Predictimmune determines which patients will have a more critical course of their pathology and thus offers a prognostic test for IBD.

On a simple blood sample, a very precise signature of 17 specific genes gives patients personalized knowledge of the future of their disease and provides the information to best adapt treatment from the start of the disease such as the possibility of making choices more enlightened lifestyle. All in all, could improve the daily management of the disease and its long-term results.